PURPOSE: The aim was to verify the impact of obesity on the long-term outcome of patients with severe SARS-CoV-2 ARDS. MATERIALS AND METHODS: The retrospective study included patients admitted to the high-volume ECMO centre between March 2020 and March 2022. The impact of body mass index (BMI), co-morbidities and therapeutic measures on the short and 90-day outcomes was analysed. RESULTS: 292 patients were included, of whom 119(40.8%) were treated with veno-venous ECMO cannulated mostly (73%) in a local hospital. 58.5% were obese (64.7% on ECMO), the ECMO was most frequent in BMI > 40(49%). The ICU mortality (36.8% for obese vs 33.9% for the non-obese, p = 0.58) was related to ECMO only for the non-obese (p = 0.04). The 90-day mortalities (48.5% obese vs 45.5% non-obese, p = 0.603) of the ECMO and non-ECMO patients were not significantly influenced by BMI (p = 0.47, p = 0.771, respectively). The obesity associated risk factors for adverse outcome were age <50 (RR 2.14) and history of chronic immunosuppressive therapy (RR 2.11, p = 0.009). The higher dosage of steroids (RR 0.57, p = 0.05) associated with a better outcome. CONCLUSIONS: The high incidence of obesity was not associated with worse short and long-term outcomes. ECMO in obese patients together with the use of steroids in the later stage of ARDS may improve survival.

Czech Institute of Informatics Robotics and Cybernetics Czech Technical University Prague Czech Republic

Department of Anesthesiology and Intensive Care 1 Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Department of Cardiovascular Surgery 1 Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Perfusion Unit Department of Cardiovascular Surgery 1 Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Citace poskytuje Crossref.org